C4 Therapeutics, Inc.

NasdaqGS:CCCC Voorraadrapport

Marktkapitalisatie: US$392.2m

C4 Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO C4 Therapeutics is Andrew Hirsch, benoemd in Sep2020, heeft een ambtstermijn van 5.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.94M, bestaande uit 23.6% salaris en 76.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde $ 481.36K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.3 jaar en 7.8 jaar.

Belangrijke informatie

Andrew Hirsch

Algemeen directeur

US$2.9m

Totale compensatie

Percentage CEO-salaris23.63%
Dienstverband CEO5.7yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijn5.3yrs
Gemiddelde ambtstermijn bestuur7.8yrs

Recente managementupdates

Recent updates

Analyseartikel • May 15

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its quarterly results, which were ahead of...
Seeking Alpha • Mar 10

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

Summary C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. CCCC's lead asset, cemsidomide, advanced into a Phase 2 registrational trial for relapsed/refractory multiple myeloma, targeting a large, growing TAM. Cash position strengthened to $297.1M, extending operational runway through 2028 and supporting continued pipeline investment. Valuation remains highly discounted (EV/sales 1.66x), but future success hinges on cemsidomide trial outcomes and regulatory milestones. Read the full article on Seeking Alpha
Analyseartikel • Dec 17

Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price

You may think that with a price-to-sales (or "P/S") ratio of 7.3x C4 Therapeutics, Inc. ( NASDAQ:CCCC ) is a stock...
Analyseartikel • Sep 05

C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33%

Despite an already strong run, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have been powering on, with a gain of 33...
Analyseartikel • Jul 11

C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have continued their recent momentum with a 27% gain in the last month...
Analyseartikel • Jun 20

We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analyseartikel • Apr 18

Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%

Unfortunately for some shareholders, the C4 Therapeutics, Inc. ( NASDAQ:CCCC ) share price has dived 40% in the last...
Seeking Alpha • Mar 10

C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here

Summary C4 Therapeutics' pipeline, including cemsidomide and CFT1946, shows early promise but faces significant safety concerns and long timelines for definitive data readouts. Financially, CCCC has sufficient cash to fund operations into 2027, reducing immediate dilution risk, but high cash burn remains a concern. Market valuation has dropped significantly, aligning more closely with their early-stage clinical status, reducing overvaluation risk. Despite potential in protein degraders, the current "Hold" sentiment is maintained due to early-stage data and lack of near-term catalysts. Read the full article on Seeking Alpha
Analyseartikel • Mar 04

C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares are down a considerable 31% in the...
Analyseartikel • Nov 15

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Nov 06

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Summary C4 Therapeutics has a promising pipeline, including cemsidomide for blood cancer and CFT1946 for solid tumors, but definitive data is still far off. Financially stable with $59.6M in cash and $196M in marketable securities, CCCC has a cash runway of 11-12 quarters, funding operations through 2025. Strengths include controlled costs and no imminent dilution risk, but the long wait for significant data readouts poses a risk for investors. Maintain a "Hold" rating; worth watching for patient, risk-tolerant investors, but not advisable to jump in headfirst just yet. Read the full article on Seeking Alpha
Analyseartikel • Oct 02

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, C4 Therapeutics...
Analyseartikel • Aug 09

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Analyseartikel • Aug 03

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Those holding C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares would be relieved that the share price has rebounded 41% in...
Analyseartikel • May 12

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Mar 01

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Summary C4 Therapeutics is developing targeted protein degraders for the treatment of various diseases, including cancer. The company's TORPEDO platform allows for the design of molecules that can break down disease-causing proteins. C4 Therapeutics has a partnership with Merck and is currently in Phase 1 clinical trials for its drug candidates. The company's current valuation appears high compared to sector peers, leading to a "hold" rating. Read the full article on Seeking Alpha
Analyseartikel • Feb 29

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Shareholders in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) may be thrilled to learn that the analysts have just delivered a...
Analyseartikel • Feb 24

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

It's been a pretty great week for C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders, with its shares surging 13% to...
Analyseartikel • Nov 03

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...

Analyse CEO-vergoeding

Hoe is Andrew Hirsch's beloning veranderd ten opzichte van C4 Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$3mUS$695k

-US$105m

Sep 30 2025n/an/a

-US$119m

Jun 30 2025n/an/a

-US$112m

Mar 31 2025n/an/a

-US$103m

Dec 31 2024US$5mUS$665k

-US$105m

Sep 30 2024n/an/a

-US$105m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$4mUS$639k

-US$132m

Sep 30 2023n/an/a

-US$135m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$131m

Dec 31 2022US$3mUS$614k

-US$128m

Sep 30 2022n/an/a

-US$107m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$952kUS$580k

-US$84m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$21mUS$168k

-US$66m

Compensatie versus markt: De totale vergoeding ($USD 2.94M ) Andrew } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.64M ).

Compensatie versus inkomsten: De vergoeding van Andrew is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Andrew Hirsch (54 yo)

5.7yrs
Tenure
US$2,940,975
Compensatie

Mr. Andrew J. Hirsch, M.B.A., is Independent Director of Akamis Bio Limited from August 2025. He is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer s...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Andrew Hirsch
CEO, President & Director5.7yrsUS$2.94m0.12%
$ 481.4k
Kenneth Anderson
Co-Founderno dataUS$85.50k0.32%
$ 1.3m
Kendra Adams
Chief Financial Officer and Head of Corporate Affairs & Treasurer2.7yrsUS$1.48m0.041%
$ 160.8k
Leonard M. Reyno
Chief Medical Officer2.8yrsUS$1.64m0.023%
$ 90.7k
Nathanael Gray
Co-Founder & Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Mark Mossler
Chief Accounting Officer2.7yrsgeen gegevens0.0053%
$ 20.6k
Paige Mahaney
Chief Scientific Officer1.6yrsgeen gegevens0.016%
$ 64.6k
Courtney Solberg
Senior Manager of Investor Relationsno datageen gegevensgeen gegevens
Kelly Schick
Chief People Officer5.3yrsgeen gegevens0.035%
$ 138.3k
Isabel Chiu
Senior Vice President of Strategic Alliances & Business Development10.2yrsgeen gegevensgeen gegevens
Christopher Nasveschuk
Senior Vice President of Chemistry5.3yrsgeen gegevensgeen gegevens
Roy Pollock
Senior Vice President of Biological Sciences7.3yrsgeen gegevensgeen gegevens
5.3yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van CCCC is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Andrew Hirsch
CEO, President & Director5.6yrsUS$2.94m0.12%
$ 481.4k
Kenneth Anderson
Co-Founder10.4yrsUS$85.50k0.32%
$ 1.3m
Nathanael Gray
Co-Founder & Member of Scientific Advisory Board9.5yrsgeen gegevensgeen gegevens
Christopher Bowden
Member of Clinical Advisory Boardno datageen gegevensgeen gegevens
Steven Hoerter
Independent Director1.5yrsUS$90.31kgeen gegevens
Christopher Kirk
Member of Scientific Advisory Board9.5yrsgeen gegevensgeen gegevens
Ross Levine
Member of Scientific Advisory Board8.8yrsgeen gegevensgeen gegevens
Ronald H. Cooper
Independent Chairman1.9yrsUS$119.25k0%
$ 0
Ryan Corcoran
Member of Scientific Advisory Board6.7yrsgeen gegevensgeen gegevens
Scott Armstrong
Member of Scientific Advisory Board8.8yrsgeen gegevensgeen gegevens
Utpal Koppikar
Independent Director4.2yrsUS$100.50k0.0051%
$ 20.2k
Beni Wolf
Member of Clinical Advisory Boardno datageen gegevensgeen gegevens
7.8yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CCCC wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/26 20:41
Aandelenkoers aan het einde van de dag2026/05/26 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

C4 Therapeutics, Inc. wordt gevolgd door 15 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Etzer DaroutBarclays
Chi Meng FongBofA Global Research
Leah Rush CannBrookline Capital Markets